Surrogate End Points and Postprogression Survival in Renal Cell Carcinoma: An Analysis of First-Line Trials With Targeted Therapies

Motzer, 2009, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 3584, 10.1200/JCO.2008.20.1293 Rini, 2010, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206, J Clin Oncol, 28, 2137, 10.1200/JCO.2009.26.5561 Escudier, 2010, Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival, J Clin Oncol, 28, 2144, 10.1200/JCO.2009.26.7849 Hotta, 2013, Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer, Lung Cancer, 79, 20, 10.1016/j.lungcan.2012.10.007 Broglio, 2009, Detecting an overall survival benefit that is derived from progression-free survival, J Natl Cancer Inst, 101, 1642, 10.1093/jnci/djp369 Petrelli, 2013, Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer, Ann Oncol, 24, 186, 10.1093/annonc/mds289 Delea, 2012, Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma, Br J Cancer, 107, 1059, 10.1038/bjc.2012.367 Johnson, 2006, Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis, Lancet Oncol, 7, 741, 10.1016/S1470-2045(06)70800-2 Sternberg, 2010, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol, 28, 1061, 10.1200/JCO.2009.23.9764 Sternberg, 2010, Randomized, double- blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (MRCC): final overall survival (OS) results, Ann Oncol, 21 Negrier, 2010, Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET, Med Oncol, 27, 899, 10.1007/s12032-009-9303-z Rini, 2008, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206, J Clin Oncol, 26, 5422, 10.1200/JCO.2008.16.9847 Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7 Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Rini, 2012, Randomized phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTERACT, Ann Oncol, 23 Motzer, 2012, Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial, Ann Oncol, 23 Rini, 2011, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, Lancet, 378, 1931, 10.1016/S0140-6736(11)61613-9 Motzer, 2010, Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors, Cancer, 116, 4256, 10.1002/cncr.25219 Sonpavde, 2012, Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?, Eur Urol, 61, 307, 10.1016/j.eururo.2011.10.032 Procopio, 2011, Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience, Expert Rev Anticancer Ther, 11, 1631, 10.1586/era.11.154 Heng, 2011, Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy, Cancer, 117, 2637, 10.1002/cncr.25750 Krajewski, 2011, Eur Urol, 59, 856, 10.1016/j.eururo.2011.01.038 Agostino, 2010, Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature, Adv Urol, 10.1155/2010/687043